Exenatide acutely increases heart rate in parallel with augmented sympathetic nervous system activation in healthy overweight males.

ABSTRACT:

Aim

Clinical use of glucagon-like peptide-1 receptor agonists (GLP-1RA) is consistently associated with heart rate (HR) acceleration in type 2 diabetes patients. We explored the mechanisms underlying this potential safety concern.

Methods

Ten healthy overweight males (aged 20-27 years) were examined in an open label, crossover study. Automated oscillometric blood pressure measurements and finger photoplethysmography were performed throughout intravenous administration of placebo (saline 0.9%), exenatide (targeting therapeutic concentrations) and a combination of exenatide and the nitric oxide synthase inhibitor L-N(G) -monomethyl arginine (L-NMMA). Sympathetic nervous system (SNS) activity was measured by heart rate variability and rate-pressure product.

Results

Exena

SUBMITTER: Smits MM 

PROVIDER: S-EPMC4799913 | biostudies-literature | 2016 Apr

REPOSITORIES: biostudies-literature